Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | IDO1 | P14902 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL11344598 | 0.91 | CYP2C9 (0.61) | CYP2C9CYP2C19MEN1KMT2AIDO1 | |
| SCHEMBL3672272 | 0.89 | CYP2C9 (0.48) | CYP2C9CYP2C19MEN1KMT2AALDH1A1 | |
| SCHEMBL17894482 | 0.85 | MAOB (0.57) | CYP2C9CYP2C19KMT2ANPC1RAB9A | |
| SCHEMBL1040794 | 0.85 | CYP2C9 (0.58) | CYP2C9CYP2C19MEN1KMT2AIDO1 | |
| Hydrochloric Acid SCHEMBL9666366 | 0.83 | CYP2C9 (0.56) | CYP2C9CYP2C19MEN1KMT2AIDO1 | |
| SCHEMBL6881703 | 0.81 | CYP2C9 (0.42) | CYP2C9CYP2C19MEN1KMT2AALOX12 | |
| SCHEMBL4103299 | 0.81 | ABAT (0.44) | CYP2C9CYP2C19MEN1KMT2AIDO1 | |
| SCHEMBL14686209 | 0.81 | TPSAB1 (0.59) | CYP2C9CYP2C19 | |
| SCHEMBL6881708 | 0.81 | EPHX2 (0.45) | CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL10592089 | 0.80 | CYP2C9 (0.56) | CYP2C9CYP2C19MEN1KMT2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656953-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656953-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-05-23 | — | — | US | disclosed |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-07 | — | — | US | disclosed |
| US-8642278-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642278-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-02-04 | — | — | US | disclosed |
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| WO-2009087395-A1 | WEIGHT REDUCING COMPOUNDS | UNIVERSITY OF STRATHCLYDE (GB) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009087395-A1 | WEIGHT REDUCING COMPOUNDS | UNIVERSITY OF STRATHCLYDE (GB) | 2009-07-16 | — | — | WO | disclosed |
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-01 | — | — | US | disclosed |
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-01 | — | — | US | disclosed |
| US-7279473-B2 | Pyrazolopyridazine derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| WO-2007062222-A2 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1463730-B1 | PYRAZOLOPYRIDAZINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050090507-A1 | Pyrazolopyridazine derivatves | SMITHKLINE BEECHAM CORPORATION | 2005-04-28 | — | — | US | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-0507317-A2 | Biguanide derivatives, manufacturing method thereof, and disinfectants containing the derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090507-A1 | Pyrazolopyridazine derivatves | CDK4, CDK3, CDK8 | CYP2C9 2654/4885CYP2C19 1882/4885MEN1 1597/4885 |
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | RB1, RAF1, NRAS | CYP2C9 4617/4885CYP2C19 4650/4885MEN1 1416/4885 |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | RB1, RAF1, NRAS | CYP2C9 4617/4885CYP2C19 4650/4885MEN1 1416/4885 |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | CYP2C9 2007/4885CYP2C19 2344/4885MEN1 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.